Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
15 Dezembro 2020 - 7:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2020.
Commission File Number: 000-53805
Intellipharmaceutics International Inc.
(Translation
of registrant's name into English)
30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F. Form 20-F [ x ]
Form 40-F [ ]
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(1):
Note: Regulation S-T Rule 101(b)(1) only permits the
submission in paper of a Form 6-K if submitted solely to provide an
attached annual report to security holders.
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(7):
Note: Regulation S-T Rule 101(b)(7) only permits the
submission in paper of a Form 6-K if submitted to furnish a report
or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the
registrant's "home country"), or under the rules of the home
country exchange on which the registrant's securities are traded,
as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant's
security holders, and, if discussing a material event, has already
been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
This
Report of Foreign Private Issuer on Form 6-K and the attached
exhibit 99.1 shall be incorporated by reference into the Company's
effective Registration Statements on Form F-3, as amended and
supplemented (Registration Statement Nos. 333-172796, 333-218297),
filed with the Securities and Exchange Commission, from the date on
which this Report is filed, to the extent not superseded by
documents or reports subsequently filed or furnished by
Intellipharmaceutics International Inc. under the Securities Act of
1933 or the Securities Exchange Act of 1934.
EXHIBIT LIST
Exhibit
|
Description
|
99.1
|
News Release dated December 15, 2020
- Intellipharmaceutics
Announces Change in Venue for The Company’s Annual General
Meeting Scheduled To Be Held on December 23,
2020
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Intellipharmaceutics
International Inc.
(Registrant)
/s/
Dr. Amina Odidi
|
Date:
December 15, 2020
|
|
Dr.
Amina Odidi
President,
Chief Operating Officer and Acting Chief Financial
Officer
|
IntelliPharmaCeutics (CE) (USOTC:IPCIF)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
IntelliPharmaCeutics (CE) (USOTC:IPCIF)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024